Posts by: Jose Marques Lopes, PhD

News

Abnormally high production of an RNA editing enzyme called ADAR1 is associated with multiple myeloma progression and resistance to treatment, according to a study. The study, “Aberrant hyperediting of myeloma ... Read more

October 12, 2018

Combination of Reolysin, Opdivo, and Standard of Care to Be Tested in Phase 1 Trial for Multiple Myeloma

News

A combination of Oncolytics Biotech’s investigational therapy Reolysin (pelareorep) with anti-cancer medication Opdivo (nivolumab) and standard of care will be tested in patients with relapsed or refractory multiple myeloma. ... Read more

October 3, 2018

EMA Begins Review Process for Empliciti Triple Combo for Relapsed or Refractory Multiple Myeloma

News

The European Medicines Agency has validated Bristol-Myers Squibb’s application for Empliciti (elotuzumab), in combination with Pomalyst (pomalidomide) and low-dose dexamethasone, for the treatment of adults with multiple myeloma. Validation confirms that the ... Read more

September 12, 2018

Poseida’s Potential CAR T-cell Therapy Shows Positive Early Results in Phase 1 Multiple Myeloma Trial

News

Poseida Therapeutics’ CAR T-cell therapy candidate P-BCMA-101 is showing superior safety over alternatives and significant effectiveness in patients with relapsed or refractory multiple myeloma, according to early results of ... Read more

September 7, 2018

Combining Simple Blood Tests Might Accelerate Diagnosis of Myeloma

News

The combination of two blood tests routinely ordered by general practitioners could speed the diagnosis of myeloma, according to a new study. The research, “Early detection of multiple myeloma ... Read more

June 4, 2018

Tilsotolimod and Yervoy Combo Seen to Shrink Tumors in Pre-treated Metastatic Melanoma Patients in Ongoing Phase 2 Trial

News

A combination of Idera Pharmaceuticals’s treatment candidate tilsotolimod plus Yervoy (ipilimumab) is able to reduce tumors in a group of patients with refractory metastatic melanoma, current results of an ongoing Phase ... Read more

May 25, 2018May 25, 2018

Trial Data Supports Darzalex Combo as Potentially Effective in Myeloma Patients Who Don’t Respond to Revlimid

News

A combination of Darzalex (daratumumab) plus Kyprolis (carfilzomib) and dexamethasone is well-tolerated and may be effective in multiple myeloma patients who fail to respond to treatment with Revlimid (lenalidomide), data from a Phase 1b ... Read more

May 7, 2018

9/11 Firefighters at Greater Risk of Multiple Myeloma Precursor, Study Reports

News

New York City firefighters exposed to the 9/11 World Trade Center (WTC) disaster are at greater risk for developing a condition called monoclonal gammopathy of undetermined significance (MGUS), which may ... Read more

March 19, 2018March 19, 2018

Myeloma Patients Refractory to Revlimid May Benefit from Ninlaro, Pomalyst, Dexamethasone Combo

News

Multiple myeloma patients who failed prior Revlimid (lenalidomide) treatment may benefit from a triple oral combo treatment with Ninlaro (ixazomib), Pomalyst (pomalidomide) and dexamethasone, the results of a Phase 1/2 clinical study ... Read more

March 9, 2018

Phase 1/2 Trial of Medigene’s MDG1011 Immunotherapy in Blood Cancer Patients Set to Begin

News

A Phase 1/2 clinical trial testing an experimental T-cell therapy for the first time in human patients will begin in the coming weeks after receiving approval from the German ... Read more